Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sanofi’s Nasacort AQ Rx-To-OTC Switch Under FDA Review

This article was originally published in The Tan Sheet

Executive Summary

FDA’s Nonprescription Drugs Advisory Committee will meet July 31 to discuss Sanofi’s application to switch the intranasal corticosteroid Nasacort AQ to OTC sale, to be indicated for relief of hay fever symptoms in adults and children.

Advertisement

Related Content

Nasacort AQ Switch Rides On “Evolution Of Data” – Sanofi CMO
Nasacort AQ Switch Rides On “Evolution Of Data” – Sanofi CMO
Allegra Brand Revision Will Sell Romance, Emotion
Pfizer Positions For First-In-Class Nasal Corticosteroid Switch
Teva Opposes Switching Asthma Drugs, Oral Contraceptives
Singulair Switch Among Merck's OTC Possibilities
Steroid Nasal Sprays Not Suitable For Rx-to-OTC Switch – Task Force

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS106464

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel